Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
CYTR's Cash to Debt is ranked higher than
92% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. CYTR: No Debt )
CYTR' s 10-Year Cash to Debt Range
Min: 0.25   Max: No Debt
Current: No Debt

Interest Coverage No Debt
CYTR's Interest Coverage is ranked higher than
71% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYTR: No Debt )
CYTR' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: -0.26
M-Score: 11.85
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -13215.67
CYTR's Operating margin (%) is ranked higher than
50% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. CYTR: -13215.67 )
CYTR' s 10-Year Operating margin (%) Range
Min: -21052   Max: -21.16
Current: -13215.67

-21052
-21.16
Net-margin (%) -16084.00
CYTR's Net-margin (%) is ranked higher than
50% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. CYTR: -16084.00 )
CYTR' s 10-Year Net-margin (%) Range
Min: -18984.04   Max: 408
Current: -16084

-18984.04
408
ROE (%) -58.08
CYTR's ROE (%) is ranked higher than
61% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. CYTR: -58.08 )
CYTR' s 10-Year ROE (%) Range
Min: -1454.89   Max: 1.33
Current: -58.08

-1454.89
1.33
ROA (%) -45.70
CYTR's ROA (%) is ranked higher than
62% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. CYTR: -45.70 )
CYTR' s 10-Year ROA (%) Range
Min: -324.66   Max: 1.11
Current: -45.7

-324.66
1.11
ROC (Joel Greenblatt) (%) -16588.70
CYTR's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. CYTR: -16588.70 )
CYTR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -444700   Max: -23.94
Current: -16588.7

-444700
-23.94
EBITDA Growth (%) -7.20
CYTR's EBITDA Growth (%) is ranked higher than
77% of the 626 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. CYTR: -7.20 )
CYTR' s 10-Year EBITDA Growth (%) Range
Min: -67.3   Max: 144.7
Current: -7.2

-67.3
144.7
» CYTR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2012

CYTR Guru Trades in Q2 2012

Jim Simons Sold Out
» More
Q4 2013

CYTR Guru Trades in Q4 2013

Steven Cohen 205,100 sh (New)
» More
Q1 2014

CYTR Guru Trades in Q1 2014

George Soros 81,800 sh (New)
Paul Tudor Jones 51,898 sh (New)
Steven Cohen Sold Out
» More
Q2 2014

CYTR Guru Trades in Q2 2014

George Soros Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CYTR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Sold Out $2.92 - $5.31 $ 2.75-27%0
George Soros 2014-03-31 New Buy$3.18 - $8.08 $ 2.75-54%81800
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.90
CYTR's P/B is ranked higher than
90% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. CYTR: 1.90 )
CYTR' s 10-Year P/B Range
Min: 1.14   Max: 64.65
Current: 1.9

1.14
64.65
P/S 1241.00
CYTR's P/S is ranked higher than
52% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. CYTR: 1241.00 )
CYTR' s 10-Year P/S Range
Min: 3.5   Max: 1241
Current: 1241

3.5
1241
EV-to-EBIT -1.06
CYTR's EV-to-EBIT is ranked higher than
50% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CYTR: -1.06 )
CYTR' s 10-Year EV-to-EBIT Range
Min: 3.1   Max: 19.2
Current: -1.06

3.1
19.2
Current Ratio 4.67
CYTR's Current Ratio is ranked higher than
74% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. CYTR: 4.67 )
CYTR' s 10-Year Current Ratio Range
Min: 1.04   Max: 75.75
Current: 4.67

1.04
75.75
Quick Ratio 4.67
CYTR's Quick Ratio is ranked higher than
76% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. CYTR: 4.67 )
CYTR' s 10-Year Quick Ratio Range
Min: 1.04   Max: 75.75
Current: 4.67

1.04
75.75

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.90
CYTR's Price/Net Cash is ranked higher than
97% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 190.00 vs. CYTR: 1.90 )
CYTR' s 10-Year Price/Net Cash Range
Min: 0.57   Max: 458
Current: 1.9

0.57
458
Price/Net Current Asset Value 1.90
CYTR's Price/Net Current Asset Value is ranked higher than
97% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 79.32 vs. CYTR: 1.90 )
CYTR' s 10-Year Price/Net Current Asset Value Range
Min: 0.44   Max: 601.65
Current: 1.9

0.44
601.65
Price/Tangible Book 1.90
CYTR's Price/Tangible Book is ranked higher than
92% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. CYTR: 1.90 )
CYTR' s 10-Year Price/Tangible Book Range
Min: 0.32   Max: 65.43
Current: 1.9

0.32
65.43
Price/Median PS Value 2.60
CYTR's Price/Median PS Value is ranked higher than
53% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. CYTR: 2.60 )
CYTR' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 11.22
Current: 2.6

0.01
11.22
Earnings Yield (Greenblatt) 44.30
CYTR's Earnings Yield (Greenblatt) is ranked higher than
90% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. CYTR: 44.30 )
CYTR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.2   Max: 57.8
Current: 44.3

5.2
57.8
Forward Rate of Return (Yacktman) -22.11
CYTR's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. CYTR: -22.11 )
CYTR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -165.8   Max: -85.3
Current: -22.11

-165.8
-85.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CX5N.Germany
CytRx Corporation is a Delaware corporation, incorporated in 1985. The Company is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes two programs in clinical development for cancer indications: aldoxorubicin (formerly known as INNO-206) and tamibarotene. With its tumor-targeted doxorubicin conjugate aldoxorubicin, it has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas, completed a Phase 1b/2 clinical trial mainly in the same indication and initiated a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors. Tamibarotene is being tested in a double-blind, placebo-controlled, international Phase 2b clinical trial in patients with non-small-cell lung cancer. Bafetinib (formerly INNO-406) is an orally bioavailable, rationally designed, inhibitor of several Src kinases developed by the Japanese pharmaceutical company Nippon Shinyaku, to overcome some of the limitations of Gleevec and other tyrosine kinase inhibitors in resistant chronic myelogenous leukemia, or CML. In addition to its Bcr-Abl inhibitory properties, bafetinib is a potent and specific inhibitor of Lyn and Fyn kinases. The Company's plan is to establish its own sales force and marketing capability in order to commercialize aldoxorubicin and tamibarotene in the U.S. and to seek a marketing partner for commercialization in other territories. It is subjected to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials.
» More Articles for CYTR

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: CYTR, API, CLGX, PLBC, ARTC Mar 05 2012 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
Weekly CFO Buys Highlight: CYTR, PZZI, AGYS, PLBC Feb 27 2012 
CytRx Corp. Reports Operating Results (10-K) Mar 11 2011 
CytRx Corp. Reports Operating Results (10-Q) Nov 08 2010 
CytRx Corp. Reports Operating Results (10-Q) Aug 09 2010 
CytRx Corp. Reports Operating Results (10-Q) May 06 2010 
CytRx Corp. Reports Operating Results (10-Q) Nov 09 2009 
CytRx Reports 2009 Second Quarter Financial Results Aug 10 2009 
CytRx Corp. Reports Operating Results (10-Q) Aug 07 2009 

More From Other Websites
CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference Sep 19 2014
Federman & Sherwood Investigates CytRx Corporation for Possible Violations of Federal Securities... Sep 16 2014
Former Louisiana Attorney General and KSF Announce Appointment as Lead Counsel in CytRx Securities... Sep 15 2014
Zeldes & Haeggquist, LLP Continues Investigation of CytRx Corporation Sep 15 2014
CytRx Initiates Phase 1b Clinical Trial with Combination of Aldoxorubicin and Ifosfamide/Mesna as... Sep 09 2014
CytRx Updates Presentation Time at Aegis 2014 Healthcare & Technology Conference Sep 05 2014
CytRx to Present at Upcoming Investor Conferences in New York City and Las Vegas Sep 02 2014
CytRx is pouring money into R&D of cancer-fighting drugs Aug 31 2014
CYTRX CORP Financials Aug 19 2014
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into CytRx... Aug 11 2014
Oral Presentation of CytRx’s Aldoxorubicin Phase 2b Clinical Trial in Soft Tissue Sarcoma... Aug 07 2014
CYTRX CORP Files SEC form 10-Q, Quarterly Report Aug 06 2014
CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 06 2014
CytRx Reports 2014 Second Quarter Financial Results Aug 06 2014
Former Louisiana Attorney General and KSF Announce Appointment as Lead Counsel in CytRx Securities... Aug 05 2014
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into CytRx... Jul 09 2014
CytRx Added to Russell 3000® and Russell 2000® Indexes Jun 30 2014
CYTRX CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 27 2014
Five Analyst Stock Picks With 100% or More Implied Upside Jun 07 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK